{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:27:34Z","timestamp":1762630054494,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010230","name":"Queensland Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:09:22Z","timestamp":1724479762000},"page":"674-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care"],"prefix":"10.1016","volume":"8","author":[{"given":"Daniel","family":"Lindsay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yaxley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Juraskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa G.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.08.005_b0005","unstructured":"Ferlay J, Laversanne M, Ervik M, et al. Global cancer observatory. Lyon, France: International Agency for Research on Cancer; 2020. https:\/\/gco.iarc.fr."},{"key":"10.1016\/j.euo.2024.08.005_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41391-019-0157-y","article-title":"Contemporary national trends in prostate cancer risk profile at diagnosis","volume":"23","author":"Fletcher","year":"2020","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2024.08.005_b0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2017.03.009","article-title":"Low-risk prostate cancer: identification, management, and outcomes","volume":"72","author":"Moschini","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0020","unstructured":"Prostate Cancer Foundation of Australia, Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Draft clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Sydney, Australia: Prostate Cancer Foundation of Australia and Cancer Council; 2016."},{"key":"10.1016\/j.euo.2024.08.005_b0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","article-title":"Active surveillance for prostate cancer: a systematic review of the literature","volume":"62","author":"Dall\u2019Era","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.08.005_b0035","doi-asserted-by":"crossref","first-page":"91.e7","DOI":"10.1016\/j.urolonc.2017.10.024","article-title":"Estimating the healthcare costs of treating prostate cancer in Australia: a Markov modelling analysis","volume":"36","author":"Gordon","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.005_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1071\/AH23231","article-title":"The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis","volume":"48","author":"Lindsay","year":"2024","journal-title":"Aust Health Rev"},{"key":"10.1016\/j.euo.2024.08.005_b0045","unstructured":"Papa N, O\u2019Callaghan M, Mark S, Millar J, Breen S. Prostate cancer across Australia and New Zealand: PCOR-ANZ 2015\u20132019 summary report. Melbourne, Australia: Monash University; 2022."},{"key":"10.1016\/j.euo.2024.08.005_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31015","article-title":"Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden","volume":"5","author":"Ventimiglia","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.08.005_b0055","first-page":"e740","article-title":"MP43-03 Active surveillance for low-risk prostate cancer: time trends and variation in the AUA Quality (AQUA) Registry","volume":"207","author":"Cooperberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clgc.2022.05.004","article-title":"Evolving trends in the management of low-risk prostate cancer","volume":"20","author":"Tzeng","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2024.08.005_b0065","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pon.3576","article-title":"\u2018What is this active surveillance thing?\u2019 Men\u2019s and partners\u2019 reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option","volume":"23","author":"O\u2019Callaghan","year":"2014","journal-title":"Psychooncology"},{"key":"10.1016\/j.euo.2024.08.005_b0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2753.2010.01517.x","article-title":"The design of patient decision support interventions: addressing the theory\u2013practice gap","volume":"17","author":"Elwyn","year":"2011","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.euo.2024.08.005_b0075","article-title":"Decision aids for people facing health treatment or screening decisions","volume":"2017","author":"Stacey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2024.08.005_b0080","first-page":"239","article-title":"Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis","volume":"65","author":"Violette","year":"2015","journal-title":"CA Cancer J Clin"},{"year":"2015","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","key":"10.1016\/j.euo.2024.08.005_b0085"},{"key":"10.1016\/j.euo.2024.08.005_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2024.08.005_b0095","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euo.2024.08.005_b0100","first-page":"1","article-title":"Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners","volume":"22","author":"Schofield","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.euo.2024.08.005_b0105","unstructured":"National Cancer Institute. Prostate: recent trends in SEER relative survival rates, 2004\u20132020. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=66&data_type=4&graph_type=2&compareBy=race&chk_race_1=1&relative_survival_interval=5&hdn_sex=2&age_range=1&stage=104&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion."},{"issue":"37","key":"10.1016\/j.euo.2024.08.005_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24370","article-title":"Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT","volume":"24","author":"Hamdy","year":"2020","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.euo.2024.08.005_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4817","article-title":"Quality of life three years after diagnosis of localised prostate cancer: population based cohort study","volume":"339","author":"Smith","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.08.005_b0120","unstructured":"Australian Bureau of Statistics. Life tables. https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-tables\/latest-release."},{"key":"10.1016\/j.euo.2024.08.005_b0125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euo.2024.08.005_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.euo.2024.08.005_b0135","unstructured":"Gordon LG, Reinking S, Mervin C. The financial impact of prostate cancer in Australia. Final report. Meadowbrook, Australia: Centre for Applied Health Economics; 2013."},{"key":"10.1016\/j.euo.2024.08.005_b0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/ans.14722","article-title":"Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update","volume":"88","author":"Wang","year":"2018","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.euo.2024.08.005_b0145","unstructured":"Australian Government Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC) guidelines. Version 4.4. Canberra, Australia: Australian Government; 2013. http:\/\/www.pbac.pbs.gov.au\/information\/table-of-contents.html."},{"key":"10.1016\/j.euo.2024.08.005_b0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0272989X08315247","article-title":"The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994\u20132004","volume":"28","author":"Harris","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euo.2024.08.005_b0155","unstructured":"Cancer Council Australia. Prostate cancer. https:\/\/www.cancer.org.au\/cancer-information\/types-of-cancer\/prostate-cancer."},{"key":"10.1016\/j.euo.2024.08.005_b0160","unstructured":"National Prostate Cancer Audit. Annual report 2020. Results of the NPCA prospective audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019. London, UK: Royal College of Surgeons of England; 2021. https:\/\/www.npca.org.uk\/content\/uploads\/2021\/01\/NPCA-Annual-Report-2020_Final_140121.pdf."},{"key":"10.1016\/j.euo.2024.08.005_b0165","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/pon.4698","article-title":"Cost-effectiveness of the BRECONDA decision aid for women with breast cancer: results from a randomized controlled trial","volume":"27","author":"Parkinson","year":"2018","journal-title":"Psychooncology"},{"key":"10.1016\/j.euo.2024.08.005_b0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.hjdsi.2014.09.002","article-title":"The cost-effectiveness of patient decision aids: a systematic review","volume":"2","author":"Trenaman","year":"2014","journal-title":"InHealthcare"},{"key":"10.1016\/j.euo.2024.08.005_b0175","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.juro.2018.06.013","article-title":"Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort","volume":"200","author":"Marzouk","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/tau.2017.12.24","article-title":"Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices","volume":"7","author":"Kinsella","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0185","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","article-title":"A decision chart for assessing and improving the transferability of economic evaluation results between countries","volume":"22","author":"Welte","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2024.08.005_b0190","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.03.011","article-title":"Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols","volume":"62","author":"Iremashvili","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.005_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-017-0726-3","article-title":"Active surveillance for intermediate risk prostate cancer","volume":"18","author":"Klotz","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euo.2024.08.005_b0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-036834","article-title":"Does the use of patient decision aids lead to cost savings? A systematic review","volume":"10","author":"Scalia","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2024.08.005_b0205","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.eururo.2018.10.055","article-title":"Cost-effectiveness analysis of active surveillance strategies for men with low-risk prostate cancer","volume":"75","author":"Sathianathen","year":"2019","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:28Z","timestamp":1762629988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931124001895"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}